DD294415A5 - Verfahren zur herstellung von 4-(2`-nitrophenyl)-2,6-dimethyl-3,5-dimethoxycarbonyl-1,4-dihydropyridin enthaltenden festen pharmazeutischen praeparaten - Google Patents
Verfahren zur herstellung von 4-(2`-nitrophenyl)-2,6-dimethyl-3,5-dimethoxycarbonyl-1,4-dihydropyridin enthaltenden festen pharmazeutischen praeparaten Download PDFInfo
- Publication number
- DD294415A5 DD294415A5 DD90338653A DD33865390A DD294415A5 DD 294415 A5 DD294415 A5 DD 294415A5 DD 90338653 A DD90338653 A DD 90338653A DD 33865390 A DD33865390 A DD 33865390A DD 294415 A5 DD294415 A5 DD 294415A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- weight
- nifedipine
- parts
- pharmaceutical preparations
- agent
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 65
- 229960001597 nifedipine Drugs 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 55
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 32
- 239000004480 active ingredient Substances 0.000 claims abstract description 27
- 239000007787 solid Substances 0.000 claims abstract description 27
- 239000003340 retarding agent Substances 0.000 claims abstract description 23
- 239000002775 capsule Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 10
- 230000003111 delayed effect Effects 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 238000013270 controlled release Methods 0.000 claims abstract description 4
- 238000007873 sieving Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 22
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 22
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 claims description 20
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 14
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 14
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 13
- 229960005168 croscarmellose Drugs 0.000 claims description 13
- 238000005507 spraying Methods 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000000454 talc Substances 0.000 claims description 10
- 229910052623 talc Inorganic materials 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 4
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920000131 polyvinylidene Polymers 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 238000007747 plating Methods 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 abstract description 13
- 239000002245 particle Substances 0.000 abstract description 11
- 238000009826 distribution Methods 0.000 abstract description 3
- 238000005204 segregation Methods 0.000 abstract description 3
- 239000007858 starting material Substances 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 24
- 239000008187 granular material Substances 0.000 description 15
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 238000005243 fluidization Methods 0.000 description 7
- 239000000049 pigment Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 5
- 230000036765 blood level Effects 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 5
- 239000001034 iron oxide pigment Substances 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 230000036211 photosensitivity Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229940067573 brown iron oxide Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000002213 calciumantagonistic effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- -1 polyoxy Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU891215A HU203041B (en) | 1989-03-14 | 1989-03-14 | Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD294415A5 true DD294415A5 (de) | 1991-10-02 |
Family
ID=10953380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD90338653A DD294415A5 (de) | 1989-03-14 | 1990-03-13 | Verfahren zur herstellung von 4-(2`-nitrophenyl)-2,6-dimethyl-3,5-dimethoxycarbonyl-1,4-dihydropyridin enthaltenden festen pharmazeutischen praeparaten |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5108757A (fr) |
| EP (1) | EP0387782B2 (fr) |
| JP (1) | JPH02279626A (fr) |
| AT (1) | AT402889B (fr) |
| BG (1) | BG91467A (fr) |
| CA (1) | CA2012194C (fr) |
| CH (1) | CH680416A5 (fr) |
| CY (1) | CY1762A (fr) |
| CZ (1) | CZ277897B6 (fr) |
| DD (1) | DD294415A5 (fr) |
| DE (1) | DE59008160D1 (fr) |
| FR (1) | FR2644343B1 (fr) |
| GB (1) | GB2229095B (fr) |
| GR (1) | GR1002295B (fr) |
| HK (1) | HK218696A (fr) |
| HU (2) | HU203041B (fr) |
| IT (1) | IT1240605B (fr) |
| RU (1) | RU1837874C (fr) |
| UA (1) | UA19285A (fr) |
| YU (1) | YU47691B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1250421B (it) * | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US5599556A (en) * | 1991-12-31 | 1997-02-04 | Abbott Laboratories | Prolamine coatings for taste masking |
| GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
| US5571533A (en) * | 1992-02-07 | 1996-11-05 | Recordati, S.A., Chemical And Pharmaceutical Company | Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide |
| WO1994005262A1 (fr) * | 1992-09-10 | 1994-03-17 | F.H. Faulding & Co. Limited | Composition sous forme de matrice a liberation prolongee |
| KR100355130B1 (ko) | 1992-09-18 | 2003-01-30 | 야마노우치세이야쿠 가부시키가이샤 | 하이드로겔서방성정제 |
| BE1006990A5 (nl) * | 1993-04-22 | 1995-02-07 | Univ Gent | Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen. |
| US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5543099A (en) * | 1994-09-29 | 1996-08-06 | Hallmark Pharmaceutical, Inc. | Process to manufacture micronized nifedipine granules for sustained release medicaments |
| JP3220373B2 (ja) * | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| DE69739165D1 (de) | 1996-07-08 | 2009-01-29 | Penwest Pharmaceuticals Co | Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe |
| US5922352A (en) * | 1997-01-31 | 1999-07-13 | Andrx Pharmaceuticals, Inc. | Once daily calcium channel blocker tablet having a delayed release core |
| US5837379A (en) * | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| US6485748B1 (en) | 1997-12-12 | 2002-11-26 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| TR200200313T2 (tr) * | 1999-08-17 | 2002-04-22 | Novartis Consumer Health S.A. | Hızla çözünen dozaj formu ve bunun yapım prosesi. |
| CA2352211C (fr) * | 1999-09-30 | 2009-03-24 | Edward Mendell Co., Inc. | Systemes de matrice a liberation prolongee pour medicaments hautement solubles |
| MXPA02005562A (es) * | 1999-12-06 | 2004-09-10 | Penwest Pharmaceuticals Co | Superdesintegrante farmaceutico. |
| CA2311734C (fr) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Forme pharmaceutique orale a dissolution ultra-rapide |
| TWI324074B (en) * | 2001-10-09 | 2010-05-01 | Bristol Myers Squibb Co | Flashmelt oral dosage formulation |
| WO2003080057A1 (fr) * | 2002-03-27 | 2003-10-02 | Bayer Aktiengesellschaft | Comprime-noyau de taille reduite contenant de la nifedipine |
| DE10315640A1 (de) * | 2003-04-04 | 2004-10-14 | Ignatov, Konstantin | Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung |
| US8128460B2 (en) * | 2006-09-14 | 2012-03-06 | The Material Works, Ltd. | Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell |
| IE20100799A1 (en) * | 2010-12-22 | 2012-08-01 | Eurand Pharmaceuticals Ltd | Pharmaceutical composites of poorly water soluble drugs and polymers |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0001247A1 (fr) * | 1977-09-14 | 1979-04-04 | Kanebo, Ltd. | Composition pharmaceutique contenant de la nifédipine et procédé pour sa préparation. |
| DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| CA1146866A (fr) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Procede de production d'un compose pharmaceutique a liberation continue sous forme solide |
| JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
| EP0078430B2 (fr) * | 1981-10-29 | 1993-02-10 | Bayer Ag | Procédé de fabrication de préparations pharmaceutiques solides à libération rapide de dihydropyridines |
| DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
| DE3424553A1 (de) * | 1984-07-04 | 1986-01-09 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung |
| IT1178511B (it) * | 1984-09-14 | 1987-09-09 | Pharmatec Spa | Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio |
| DE3438830A1 (de) * | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| EP0207638B1 (fr) * | 1985-06-04 | 1990-12-19 | Teijin Limited | Préparation pharmaceutique à liberation prolongé |
| IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
| IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
| IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
| GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| DE3636123A1 (de) * | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten |
| DE3639073A1 (de) * | 1986-11-14 | 1988-05-26 | Klinge Co Chem Pharm Fab | Feste arzneizubereitungen und verfahren zu ihrer herstellung |
| IE59540B1 (en) * | 1987-01-09 | 1994-03-09 | Elan Corp | Sustained release capsule or tablet formulation |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
-
1989
- 1989-03-14 HU HU891215A patent/HU203041B/hu unknown
-
1990
- 1990-03-07 YU YU45890A patent/YU47691B/sh unknown
- 1990-03-12 GR GR900100179A patent/GR1002295B/el unknown
- 1990-03-12 CH CH789/90A patent/CH680416A5/de not_active IP Right Cessation
- 1990-03-13 DD DD90338653A patent/DD294415A5/de not_active IP Right Cessation
- 1990-03-13 EP EP90104718A patent/EP0387782B2/fr not_active Expired - Lifetime
- 1990-03-13 DE DE59008160T patent/DE59008160D1/de not_active Expired - Fee Related
- 1990-03-14 US US07/493,283 patent/US5108757A/en not_active Expired - Fee Related
- 1990-03-14 GB GB9005730A patent/GB2229095B/en not_active Expired - Fee Related
- 1990-03-14 FR FR909003243A patent/FR2644343B1/fr not_active Expired - Fee Related
- 1990-03-14 BG BG091467A patent/BG91467A/bg unknown
- 1990-03-14 RU SU904743502A patent/RU1837874C/ru active
- 1990-03-14 AT AT0060690A patent/AT402889B/de not_active IP Right Cessation
- 1990-03-14 JP JP2061335A patent/JPH02279626A/ja active Pending
- 1990-03-14 CA CA002012194A patent/CA2012194C/fr not_active Expired - Fee Related
- 1990-03-14 UA UA4743502A patent/UA19285A/uk unknown
- 1990-03-14 CZ CS901237A patent/CZ277897B6/cs unknown
- 1990-03-14 IT IT19677A patent/IT1240605B/it active IP Right Grant
-
1994
- 1994-07-15 CY CY176294A patent/CY1762A/xx unknown
-
1995
- 1995-06-20 HU HU95P/P00270P patent/HU211507A9/hu unknown
-
1996
- 1996-12-24 HK HK218696A patent/HK218696A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE59008160D1 (de) | 1995-02-16 |
| IT9019677A0 (it) | 1990-03-14 |
| YU47691B (sh) | 1996-01-08 |
| HU211507A9 (en) | 1995-11-28 |
| GR900100179A (el) | 1991-07-31 |
| GR1002295B (el) | 1996-05-03 |
| JPH02279626A (ja) | 1990-11-15 |
| CA2012194A1 (fr) | 1990-09-14 |
| BG91467A (bg) | 1993-12-24 |
| FR2644343B1 (fr) | 1994-10-21 |
| EP0387782B1 (fr) | 1995-01-04 |
| CA2012194C (fr) | 1995-10-31 |
| YU45890A (en) | 1992-05-28 |
| EP0387782A3 (fr) | 1991-03-13 |
| IT1240605B (it) | 1993-12-17 |
| AT402889B (de) | 1997-09-25 |
| IT9019677A1 (it) | 1991-09-14 |
| EP0387782B2 (fr) | 1996-11-06 |
| EP0387782A2 (fr) | 1990-09-19 |
| CZ277897B6 (en) | 1993-06-16 |
| ATA60690A (de) | 1997-02-15 |
| HK218696A (en) | 1997-01-03 |
| HU203041B (en) | 1991-05-28 |
| GB2229095B (en) | 1993-02-10 |
| GB2229095A (en) | 1990-09-19 |
| FR2644343A1 (fr) | 1990-09-21 |
| RU1837874C (ru) | 1993-08-30 |
| HUT54046A (en) | 1991-01-28 |
| US5108757A (en) | 1992-04-28 |
| UA19285A (uk) | 1997-12-25 |
| GB9005730D0 (en) | 1990-05-09 |
| CY1762A (en) | 1994-07-15 |
| CH680416A5 (fr) | 1992-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD294415A5 (de) | Verfahren zur herstellung von 4-(2`-nitrophenyl)-2,6-dimethyl-3,5-dimethoxycarbonyl-1,4-dihydropyridin enthaltenden festen pharmazeutischen praeparaten | |
| DE60210315T2 (de) | Tamsulosin tabletten | |
| AT392901B (de) | Verfahren zur herstellung einer granulaeren form mit verzoegerter freisetzung von pharmazeutisch wirksamen substanzen | |
| DE69414046T3 (de) | Morphinenthaltende Arzneizusammensetzungen mit verzögerter Wirkstoffabgabe | |
| AT394310B (de) | Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge | |
| DE69233699T2 (de) | Oxycodonzusammensetzungen mit kontrollierter Freisetzung | |
| EP0068191B2 (fr) | Formes orales du dipyridamole | |
| DE69629755T2 (de) | Irbesartanhaltiges Arzneimittel | |
| DE60224096T3 (de) | Verfahren zur herstellung einer zweischichtigen pharmazeutischen tablette enthaltend telmisartan und hydrochlorothiazid | |
| DE69535445T2 (de) | Schmelzextrudierte oral verabreichbare Opioidformulierungen | |
| DE60208673T2 (de) | Umhüllte pellets auf basis eines ace-hemmers | |
| AT3413U2 (de) | Arzneimittel mit kontrollierter freisetzung von tramadol | |
| DE3431861A1 (de) | Pellet-zubereitung | |
| EP0052076B1 (fr) | Comprimé pharmaceutique à désagrégation rapide | |
| DE3024858A1 (de) | Anhaltend freigebende pharmazeutische zubereitung eines festen medikamentmaterials | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| WO2000016748A1 (fr) | Preparations pharmaceutiques a liberation controlee en fonction de l'agitation et leur procede de production | |
| DE202005020881U1 (de) | Psychostimulans enthaltende pharmazeutische Zusammensetzung | |
| DE60130270T2 (de) | Verfahren zur herstellung einer pharmazeutischen zubereitung mit 5-aminosalicylsäure zur verwendung bei der behandlung von colitis ulcerosa und morbus crohn | |
| EP0691843B1 (fr) | Micro-comprime retard de derives de beta-phenylpropiophenone | |
| EP0267386A1 (fr) | Préparations pharmaceutiques solides et procédé pour leur fabrication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |